The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durvalumab + tremelimumab in biologically selected advanced/metastatic solid tumors.
 
Christelle De La Fouchardiere
Honoraria - Merck Serono; Merck Serono; Roche; Roche
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Eisai; Incyte; Ipsen; Ipsen; Lilly; MSD Oncology; Pierre Fabre; Roche; SERVIER
Research Funding - Pierre Fabre (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; Pierre Fabre; Roche; SERVIER; SERVIER
Other Relationship - Amgen; Incyte; MSD Oncology
 
Carlos A. Gomez-Roca
Honoraria - Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Ellipses Pharma; Macomics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech
Travel, Accommodations, Expenses - MSD Oncology; Pierre Fabre; Roche/Genentech
 
Aymeric De Montfort
No Relationships to Disclose
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Marine Gilabert
No Relationships to Disclose
 
Olivier Tredan
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Eisai Europe; Gilead Sciences; Lilly; MSD Oncology; Pfizer; Pierre Fabre; Roche; Sandoz-Novartis; Seagen; Stemline Therapeutics; Viatris
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; MSD Oncology; Novartis; Pfizer; Roche
 
Iphig nie Korakis
No Relationships to Disclose
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; DECIPHERA; Genmab; GlaxoSmithKline; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Blueprint Medicines; BMS; Bristol-Myers Squibb; Clovis Oncology; Daichi; Deciphera; Eisai; Genmab; GlaxoSmithKline; Macrogenics; Mersana; MSD Oncology; Novartis; Novocure; Ose pharma; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES
 
Pauline Rochefort
No Relationships to Disclose
 
Armelle Dufresne
No Relationships to Disclose
 
Sophie Cousin
No Relationships to Disclose
 
Christophe Le Tourneau
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Novartis; Rakuten Medical; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD
 
Benoit You
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Daiichi Sankyo Europe GmbH; ECS PROGASTRIN; GlaxoSmithKline; Immunomedics; LEK; MSD Oncology; Myriad Genetics; Novartis; Roche/Genentech; Seagen; TESARO
Research Funding - Clovis Oncology (Inst); Merck Serono (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; MSD Oncology; Roche/Genentech; SEAGEN
 
Francois Bertucci
No Relationships to Disclose
 
Philippe Alexandre Cassier
Honoraria - Amgen
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Janssen Oncology; OSE Immunotherapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
 
Valéry Attignon
No Relationships to Disclose
 
Romaine Mayet
No Relationships to Disclose
 
Gwenaelle Garin
No Relationships to Disclose
 
David Pérol
Honoraria - AstraZeneca; BMS; DAIICHI SANKYO; Lilly; MSD; Novartis; Roche; TAKEDA
Travel, Accommodations, Expenses - Roche
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche